Rac family small GTPase 1 pseudogene 9Genealiases: []
Q-omics provides the consensus-scored RAC1P9 profile across patient tissues and cancer cell-line models. RAC1P9 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RAC1P9 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, RAC1P9 RNA expression shows 7,554 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, BRCA, and TGCT as cancer lineages where RAC1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAC1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAC1P9 survival associations across molecular data types. RAC1P9 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAC1P9 RNA expression–survival associations across cancer types. High RAC1P9 expression shows unfavorable associations in STAD, COAD, CHOL, KIRC, KICH and THCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RAC1P9 RNA expression.
This table summarizes RAC1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RAC1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAC1P9 shows higher tumor expression in BRCA, BLCA, LUAD and LIHC. The BRCA box plot shows higher RAC1P9 RNA expression in tumor versus normal tissue (log2 FC = +0.024, t-test p = .009).
This table shows molecular features associated with RAC1P9 in patient tissues and cancer cell lines. In patient samples, RAC1P9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
